

PROVIDER Update



CONTRACTUAL | APRIL 1, 2026 | UPDATE 26-415m | 7 PAGES

Medication Trend Updates and Drug List/Formulary Changes – 2nd Quarter 2026

Review drug list, formulary and drug benefit changes, and medication safety issues

Stay up to date with information about:

- FDA seeks removal of suicide warnings on GLP-1 weight loss drugs
- Changes to the Health Net* Commercial Formulary, Medi-Cal Drug Lists and Medicare Part D Formulary drug benefit changes for the second quarter of 2026

FDA seeks removal of suicide warnings on GLP-1 weight loss drugs

The Food and Drug Administration (FDA) requested that manufacturers of glucagon-like peptide-1 receptor agonist (GLP-1 RA) remove warnings related to suicidal ideation and behavior (SI/B) from product labeling.

The affected products include:

- Novo Nordisk's Saxenda® (liraglutide)
- Novo Nordisk's Wegovy® (semaglutide)
- Eli Lilly's Zepbound® (tirzepatide)

This request follows a comprehensive FDA review that found no increased risk of SI/B associated with GLP-1 RA use. A meta-analysis of 91 placebo-controlled trials involving 107,910 patients also showed no increased risk of psychiatric adverse events with GLP-1 medications.

Notably, GLP-1 RA products approved for the treatment of type 2 diabetes mellitus do not currently include SI/B risk information in their labeling. To ensure consistent messaging across all FDA-approved GLP-1 RA products, the FDA is requesting removal of this warning from the prescribing information for Saxenda®, Wegovy®, and Zepbound®.

Healthcare professionals should be prepared to inform patients that, based on a comprehensive review of available data, the FDA has found no increased risk of suicidal ideation or behavior associated with these medications.

THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians and Practitioners
- Participating Physician Groups

LINES OF BUSINESS:

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter PPO
- Employer Group
 - HMO/POS
 - PPO
- Medicare Advantage (HMO) (Wellcare By Health Net)
- Medi-Cal
 - Amador
 - Calaveras
 - Inyo
 - Los Angeles
 - Molina
 - Mono
 - Sacramento
 - San Joaquin
 - Stanislaus
 - Tulare
 - Tuolumne

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP

Ambetter PPO – 844-463-8188

Ambetter HMO – 888-926-2164

Health Net Employer Group HMO, POS & PPO – 800-641-7761

Medicare (individual & employer group) (Wellcare By Health Net) – 800-929-9224

Medicare Supplement – 800-641-7761

Medi-Cal (including CS and ECM providers) – 800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

Source: FDA news release at https://bit.ly/FDA_Removal_GLP-1_WeightLossDrug

Changes to Commercial, Medicare Part D and Medi-Cal drug lists/formulary

The Pharmacy Advisory Committee is made up of participating physicians, pharmacists and other healthcare professionals. Every quarter, the committee reviews drug lists/formularies and medication benefits for Commercial, Medicare Part D (for Medicare members) and Medi-Cal members. They decide which medications stay on the same tier and which ones move to a different tier.

A table showing some of the recent changes for **Q2 2026** is available on **pages 3-7**. It includes:

- Medication names
- Their updated formulary status
- Formulary alternative options
- Notes or comments

You can find the full formulary/drug lists for Commercial, Medi-Cal and Medicare Part D on the *Pharmacy Information for Providers* page at <https://bit.ly/PharmacyInformationforProviders>.

For medical drug benefits, refer to the *Outpatient Pharmaceuticals (Submitted Under Medical Benefit)* section on the Medi-Cal Fee-for-Service **Prior Authorization List** at <https://bit.ly/HealthNetPriorAuthorizations>.

Pharmacy help line

For more information regarding changes to the Health Net Commercial Formularies, Medi-Cal medication benefits or drug list, or Medicare Part D Formulary, contact the proper pharmacy phone numbers listed below:

| Product | Phone number | Fax number |
|---|------------------------|-------------------|
| Pharmacy Benefit (Medi-Cal Rx) | 800-977-2273 | 800-869-4325 |
| Medical Benefit Drugs (Medi-Cal) | 800-867-6564, option 2 | 833-953-3436 |
| Commercial Pharmacy Services | 800-548-5524, option 2 | 800-314-6223 |
| Medicare Pharmacy Service Center | 800-867-6564, option 1 | 800-977-8226 |

Need help? Contact us

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by email at **provider_services@healthnet.com**, by phone or through the Health Net provider portal as listed in the right-hand column on page 1.

Health Net Commercial Drug Lists, Medicare Part D Formulary and Medi-Cal medication benefit changes

Note: The information on the tables is subject to change. For the most current details, please refer to the Prior Authorization List at <https://bit.ly/HealthNetPriorAuthorizations>.

| Medication | Status | | | Health Net Formulary Alternative(s) | | | Comments |
|------------------------------------|--------------------------------------|------------------------------|---------------------|---|---|---------------------|--|
| | Commercial Tier 3 plan (Tier 4 plan) | Medicare Part D ¹ | Medi-Cal | Commercial (Tier 1 or 2) | Medicare Part D Value ¹ | Medi-Cal | |
| Nasal preparation | | | | | | | |
| Cardamyst™ (etripamil) nasal spray | NF | NF | Carved out to state | diltiazem, verapamil atenolol, metoprolol, nadolol, propranolol flecainide, propafenone | diltiazem, verapamil atenolol, metoprolol, nadolol, propranolol flecainide, propafenone | Carved out to state | A calcium channel blocker indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults |
| Oral preparation | | | | | | | |
| Hyrnuo® (sevabertinib) tablet | NF | NF | Carved out to state | | | | A kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy |

¹Medicare Part D: Wellcare CalViva Health Dual Align (HMO D-SNP), Wellcare Dual Align (HMO D-SNP), Wellcare Dual Liberty (HMO D-SNP), Wellcare Low Premium (HMO), Wellcare Simple Focus (HMO), Wellcare Simple Ruby (HMO), Wellcare Premium Ultra (HMO), Wellcare Specialty Simple (HMO C-SNP), Wellcare CalViva Health Dual Align (HMO D-SNP), Wellcare Dual Align (HMO D-SNP), Wellcare Dual Liberty (HMO D-SNP).

NF indicates nonformulary; NP indicates nonpreferred. These medications require member-specific medical reasons why formulary medications cannot be considered. Requests are reviewed via Health Net's prior authorization process.

Health Net Commercial Drug Lists, Medicare Part D Formulary and Medi-Cal medication benefit changes, *continued*

| Medication | Status | | | Health Net Formulary Alternative(s) | | | Comments |
|---|--------------------------------------|------------------------------|---------------------|--|------------------------------------|---------------------|--|
| | Commercial Tier 3 plan (Tier 4 plan) | Medicare Part D ¹ | Medi-Cal | Commercial (Tier 1 or 2) | Medicare Part D Value ¹ | Medi-Cal | |
| Oral preparation | | | | | | | |
| Komzifti™ (ziftomenib) capsule | NF | NF | Carved out to state | | | | A menin inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options |
| Kygevvi™ (doxycitine and doxribtimine) powder for oral solution | NF | NF | Carved out to state | | | | A combination of doxycitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years |
| Lynkuet® (elinzanetant) capsule | NF | NF | Carved out to state | Estradiol Menest® Premarin® Premphase® Prempro® | Estradiol | Carved out to state | A neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause |

¹Medicare Part D: Wellcare CalViva Health Dual Align (HMO D-SNP), Wellcare Dual Align (HMO D-SNP), Wellcare Dual Liberty (HMO D-SNP), Wellcare Low Premium (HMO), Wellcare Simple Focus (HMO), Wellcare Simple Ruby (HMO), Wellcare Premium Ultra (HMO), Wellcare Specialty Simple (HMO C-SNP), Wellcare CalViva Health Dual Align (HMO D-SNP), Wellcare Dual Align (HMO D-SNP), Wellcare Dual Liberty (HMO D-SNP).

NF indicates nonformulary; NP indicates nonpreferred. These medications require member-specific medical reasons why formulary medications cannot be considered. Requests are reviewed via Health Net's prior authorization process.

Health Net Commercial Drug Lists, Medicare Part D Formulary and Medi-Cal medication benefit changes, *continued*

| Medication | Status | | | Health Net Formulary Alternative(s) | | | Comments |
|---|--------------------------------------|------------------------------|---------------------|--|--|---------------------|--|
| | Commercial Tier 3 plan (Tier 4 plan) | Medicare Part D ¹ | Medi-Cal | Commercial (Tier 1 or 2) | Medicare Part D Value ¹ | Medi-Cal | |
| Oral preparation | | | | | | | |
| Myqorzo® (aficamten) film-coated tablet | NF | NF | Carved out to state | disopyramide Beta-blockers: atenolol, bisoprolol, metoprolol, propranolol Calcium-channel blockers: diltiazem, verapamil | disopyramide Beta-blockers: atenolol, bisoprolol, metoprolol, propranolol Calcium-channel blockers: diltiazem, verapamil | Carved out to state | A cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms |

¹Medicare Part D: Wellcare CalViva Health Dual Align (HMO D-SNP), Wellcare Dual Align (HMO D-SNP), Wellcare Dual Liberty (HMO D-SNP), Wellcare Low Premium (HMO), Wellcare Simple Focus (HMO), Wellcare Simple Ruby (HMO), Wellcare Premium Ultra (HMO), Wellcare Specialty Simple (HMO C-SNP), Wellcare CalViva Health Dual Align (HMO D-SNP), Wellcare Dual Align (HMO D-SNP), Wellcare Dual Liberty (HMO D-SNP).

NF indicates nonformulary; NP indicates nonpreferred. These medications require member-specific medical reasons why formulary medications cannot be considered. Requests are reviewed via Health Net's prior authorization process.

Health Net Commercial Drug Lists, Medicare Part D Formulary and Medi-Cal medication benefit changes, *continued*

| Medication | Status | | | Health Net Formulary Alternative(s) | | | Comments |
|------------|--------------------------------------|------------------------------|----------|-------------------------------------|------------------------------------|----------|----------|
| | Commercial Tier 3 plan (Tier 4 plan) | Medicare Part D ¹ | Medi-Cal | Commercial (Tier 1 or 2) | Medicare Part D Value ¹ | Medi-Cal | |

Injectable preparation

| | | | | | | | |
|--|------------------------------|------------------------------|------------------------------|--|--|---------------------|--|
| Exdensur® (depemokimab-ulaa) single-dose prefilled syringe/pen | Medical benefit ² | Medical benefit ² | Medical benefit ² | Inhaled corticosteroids (ICS): budenoside, fluticasone, Qvar® Long-acting beta-2 agonists (LABA): Serevent® Combination ICS+LABA: budenoside/formoterol, fluticasone/salmeterol, Breo Ellipta® Leukotriene modifier: montelukast, zafirlukast | Inhaled corticosteroids (ICS): budenoside, Arnuity® Ellipta® Long-acting beta-2 agonists (LABA): Serevent Combination ICS+LABA: fluticasone/salmeterol, Breo Ellipta® Leukotriene modifier: montelukast, zafirlukast | Carved out to state | An interleukin-5 (IL-5) antagonist, a monoclonal antibody (humanized immunoglobulin G [IgG]1 kappa) indicated for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older |
|--|------------------------------|------------------------------|------------------------------|--|--|---------------------|--|

¹Medicare Part D: Wellcare CalViva Health Dual Align (HMO D-SNP), Wellcare Dual Align (HMO D-SNP), Wellcare Dual Liberty (HMO D-SNP), Wellcare Low Premium (HMO), Wellcare Simple Focus (HMO), Wellcare Simple Ruby (HMO), Wellcare Premium Ultra (HMO), Wellcare Specialty Simple (HMO C-SNP), Wellcare CalViva Health Dual Align (HMO D-SNP), Wellcare Dual Align (HMO D-SNP), Wellcare Dual Liberty (HMO D-SNP).

²Prior authorization is required to verify that the member is eligible and satisfies clinical protocols to ensure appropriate use of the medication.

Health Net Commercial Drug Lists, Medicare Part D Formulary and Medi-Cal medication benefit changes, *continued*

| Medication | Status | | | Health Net Formulary Alternative(s) | | | Comments |
|--|--------------------------------------|------------------------------|------------------------------|--|--|---------------------|---|
| | Commercial Tier 3 plan (Tier 4 plan) | Medicare Part D ¹ | Medi-Cal | Commercial (Tier 1 or 2) | Medicare Part D Value ¹ | Medi-Cal | |
| Injectable preparation | | | | | | | |
| Lerochol™ (lerodalcibep-liga) single-dose prefilled syringe | Medical benefit ² | Medical benefit ² | Medical benefit ² | ezetimibe, ezetimibe/simvastatin, atorvastatin, fluvastatin, pravastatin, rosuvastatin | ezetimibe, ezetimibe/simvastatin, atorvastatin, fluvastatin, pravastatin, rosuvastatin | Carved out to state | A proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) |
| Waskyra™ (etuvetidigene autotemcel) suspension for intravenous use | Medical benefit ² | Medical benefit ² | Medical benefit ² | | | | An autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients aged six months and older and adults with Wiskott-Aldrich Syndrome (WAS) who have a mutation in the WAS gene for whom hematopoietic stem cell transplantation (HSCT) is appropriate and no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available |

¹Medicare Part D: Wellcare CalViva Health Dual Align (HMO D-SNP), Wellcare Dual Align (HMO D-SNP), Wellcare Dual Liberty (HMO D-SNP), Wellcare Low Premium (HMO), Wellcare Simple Focus (HMO), Wellcare Simple Ruby (HMO), Wellcare Premium Ultra (HMO), Wellcare Specialty Simple (HMO C-SNP), Wellcare CalViva Health Dual Align (HMO D-SNP), Wellcare Dual Align (HMO D-SNP), Wellcare Dual Liberty (HMO D-SNP).

²Prior authorization is required to verify that the member is eligible and satisfies clinical protocols to ensure appropriate use of the medication.